Catalogo Articoli (Spogli Riviste)

HELP
ATTENZIONE: attualmente gli articoli Current Contents (fonte ISI) a partire dall'anno 2002 sono consultabili sulla Risorsa On-Line

Le informazioni sugli articoli di fonte ISI sono coperte da copyright

La ricerca find articoli where soggetti phrase all words 'motor fluctuations' sort by level,fasc_key/DESCEND, pagina_ini_num/ASCEND ha restituito 250 riferimenti
Si mostrano 100 riferimenti a partire da 1
Selezionare un intervallo

Per ulteriori informazioni selezionare i riferimenti di interesse.

    1. Nutt, JG
      Motor fluctuations and dyskinesia in Parkinson's disease

      PARKINSONISM & RELATED DISORDERS
    2. Joyce, JN; Ryoo, H; Gurevich, EV; Adler, C; Beach, T
      Ventral striatal D-3 receptors and Parkinson's disease

      PARKINSONISM & RELATED DISORDERS
    3. Caraceni, T; Musicco, M
      Levodopa or dopamine agonists, or deprenyl as initial treatment for Parkinson's disease. A randomized multicenter study

      PARKINSONISM & RELATED DISORDERS
    4. Depatie, L; Lal, S
      Apomorphine and the dopamine hypothesis of schizophrenia: a dilemma?

      JOURNAL OF PSYCHIATRY & NEUROSCIENCE
    5. Rubenstein, LM; DeLeo, A; Chrischilles, EA
      Economic and health-related quality of life considerations of new therapies in Parkinson's disease

      PHARMACOECONOMICS
    6. Erdal, KJ
      Depression and anxiety in persons with Parkinson's disease with and without "on-off" phenomena

      JOURNAL OF CLINICAL PSYCHOLOGY IN MEDICAL SETTINGS
    7. Furlanut, M; Furlanut, M; Benetello, P
      Monitoring of L-dopa concentrations in Parkinson's disease

      PHARMACOLOGICAL RESEARCH
    8. Lieberman, A; Minagar, A; Pinter, MM
      The efficacy of pramipexole in the treatment of Parkinson's disease

      REVIEWS IN CONTEMPORARY PHARMACOTHERAPY
    9. Marin, C; Jimenez, A; Bonastre, M; Vila, M; Agid, Y; Hirsch, EC; Tolosa, E
      LY293558, an AMPA glutamate receptor antagonist, prevents and reverses levodopa-induced motor alterations in parkinsonian rats

      SYNAPSE
    10. Hardoff, R; Sula, M; Tamir, A; Soil, A; Front, A; Badarna, S; Honigman, S; Giladi, N
      Gastric emptying time and gastric motility in patients with Parkinson's disease

      MOVEMENT DISORDERS
    11. Koller, W; Lees, A; Doder, M; Hely, M
      Randomized trial of tolcapone versus pergolide as add-on to levodopa therapy in Parkinson's disease patients with motor fluctuations

      MOVEMENT DISORDERS
    12. Ahlskog, JE; Muenter, MD
      Frequency of levodopa-related dyskinesias and motor fluctuations as estimated from the cumulative literature

      MOVEMENT DISORDERS
    13. Jankovic, J
      Parkinson's diseasetherapy: treatment of early and late disease

      CHINESE MEDICAL JOURNAL
    14. Djaldetti, R; Rosmarin, V; Ziv, I; Melamed, E
      The pharmacokinetic profile of the "first ever" oral dose of levodopa in de novo patients with Parkinson's disease

      CLINICAL NEUROPHARMACOLOGY
    15. Djaldetti, R; Melamed, E
      New therapies for Parkinson's disease

      JOURNAL OF NEUROLOGY
    16. Wang, J; Liu, ZL; Chen, B
      Dopamine D5 receptor gene polymorphism and the risk of levodopa-induced motor fluctuations in patients with Parkinson's disease

      NEUROSCIENCE LETTERS
    17. Fredriksson, A; Danysz, W; Quack, G; Archer, T
      Co-administration of memantine and amantadine with sub/suprathreshold doses of L-Dopa restores motor behaviour of MPTP-treated mice

      JOURNAL OF NEURAL TRANSMISSION
    18. Mungersdorf, M; Sommer, U; Sommer, M; Reichmann, H
      High-dose therapy with ropinirole in patients with Parkinson's disease

      JOURNAL OF NEURAL TRANSMISSION
    19. Contin, M; Riva, R; Martinelli, P; Albani, F; Avoni, P; Baruzzi, A
      Levodopa therapy monitoring in patients with Parkinson disease: a kinetic-dynamic approach

      THERAPEUTIC DRUG MONITORING
    20. Najib, J
      Entacapone: A catechol-O-methyltransferase inhibitor for the adjunctive treatment of Parkinson's disease

      CLINICAL THERAPEUTICS
    21. Etminan, M; Samii, A; Takkouche, B; Rochon, PA
      Increased risk of somnolence with the new dopamine agonists in patients with Parkinson's disease - A meta-analysis of randomised controlled trials

      DRUG SAFETY
    22. Agid, Y
      Levodopa - Is toxicity a myth?

      NEUROLOGY
    23. Rice, JE; Thompson, PD
      Movement disorders I: Parkinsonism and the akinetic-rigid syndromes

      MEDICAL JOURNAL OF AUSTRALIA
    24. Manson, AJ; Hanagasi, H; Turner, K; Patsalos, PN; Carey, P; Ratnaraj, N; Lees, AJ
      Intravenous apomorphine therapy in Parkinson's disease - Clinical and pharmacokinetic observations

      BRAIN
    25. Dewey, RB; Hutton, JT; LeWitt, PA; Factor, SA
      A randomized, double-blind, placebo-controlled trial of subcutaneously injected apomorphine for Parkinsonian off-state events

      ARCHIVES OF NEUROLOGY
    26. Shoulson, I; Lang, A; Fahn, S; McDermott, M; Kieburtz, K; Schwid, S; Kayson, E; Chase, T; Greenamyre, T; Penney, J; Frucht, S; Winfield, H; Goetz, C; Blasucci, L; Nutt, J; Carter, J; Morehouse, S; Rajput, A; Ewanishin, M; Johnston, L; Casaceli, C; Day, D; Hodgeman, K; Laroia, N; de Marcaida, JA; Orme, C; Watts, A; Natarajan, R; Huang, P; Tariot, P; Cox, C; Leventhal, C
      Evaluation of dyskinesias in a pilot, randomized, placebo-controlled trialof remacemide in advanced Parkinson disease

      ARCHIVES OF NEUROLOGY
    27. Nilsson, D; Nyholm, D; Aquilonius, SM
      Duodenal levodopa infusion in Parkinson's disease - long-term experience

      ACTA NEUROLOGICA SCANDINAVICA
    28. Brooks, DJ; Forsyth, D; Playfer, JR; Williams, AC
      The role of entacapone in the management of Parkinson's disease

      HOSPITAL MEDICINE
    29. Stern, MB
      The early treatment of Parkinson's disease: levodopa, dopamine agonists orboth

      PARKINSONISM & RELATED DISORDERS
    30. Rinne, UK
      Treatment of early Parkinson's disease

      PARKINSONISM & RELATED DISORDERS
    31. Kondo, T
      Treatment of Parkinson's disease in Japan

      PARKINSONISM & RELATED DISORDERS
    32. Olanow, CW; Stocchi, F
      Why delaying levodopa is a good treatment strategy in early Parkinson's disease

      EUROPEAN JOURNAL OF NEUROLOGY
    33. Contin, M; Riva, R; Albani, F; Baruzzi, A
      Pharmacokinetic optimisation of dopamine receptor agonist therapy for Parkinson's disease

      CNS DRUGS
    34. Bonnet, AM
      Involvement of non-dopaminergic pathways in Parkinson's disease - Pathophysiology and therapeutic implications

      CNS DRUGS
    35. Kulisevsky, J
      Role of dopamine in learning and memory - Implications for the treatment of cognitive dysfunction in patients with Parkinson's disease

      DRUGS & AGING
    36. Young, LR; Justice, LN
      Parkinson's disease: Focus on management alternatives

      AMERICAN JOURNAL OF MANAGED CARE
    37. Hely, MA; Fung, VSC; Morris, JGL
      Treatment of Parkinson's disease

      JOURNAL OF CLINICAL NEUROSCIENCE
    38. Henderson, MJ; Mellers, JDC
      Psychosis in Parkinson's disease: 'between a rock and a hard place'

      INTERNATIONAL REVIEW OF PSYCHIATRY
    39. Marin, C; Jimenez, A; Bonastre, M; Chase, TN; Tolosa, E
      Non-NMDA receptor-mediated mechanisms are involved in levodopa-induced motor response alterations in parkinsonian rats

      SYNAPSE
    40. Poewe, W; Wenning, GK
      Apomorphine: An underutilized therapy for Parkinson's disease

      MOVEMENT DISORDERS
    41. Luginger, E; Wenning, GK; Bosch, S; Poewe, W
      Beneficial effects of amantadine on L-Dopa-induced dyskinesias in Parkinson's disease

      MOVEMENT DISORDERS
    42. Goetz, CG; Stebbins, GT; Blasucci, LM
      Differential progression of motor impairment in levodopa-treated Parkinson's disease

      MOVEMENT DISORDERS
    43. Factor, SA; Molho, ES
      Emergency department presentations of patients with Parkinson's disease

      AMERICAN JOURNAL OF EMERGENCY MEDICINE
    44. Metman, LV; Del Dotto, P; LePoole, K; Konitsiotis, S; Fang, J; Chase, TN
      Amantadine for levodopa-induced dyskinesias

      NERVENHEILKUNDE
    45. Ogawa, N
      Factors affecting levodopa effects in Parkinson's disease

      ACTA MEDICA OKAYAMA
    46. Bejjani, BP; Arnulf, I; Demeret, S; Damier, P; Bonnet, AM; Houeto, JL; Agid, Y
      Levodopa-induced dyskinesias in Parkinson's disease: Is sensitization reversible?

      ANNALS OF NEUROLOGY
    47. Calabresi, P; Giacomini, P; Centonze, D; Bernardi, G
      Levodopa-induced dyskinesia: A pathological form of striatal synaptic plasticity?

      ANNALS OF NEUROLOGY
    48. Nutt, JG
      Clinical pharmacology of levodopa-induced dyskinesia

      ANNALS OF NEUROLOGY
    49. Rabey, JM; Sagi, I; Huberman, M; Melamed, E; Korczyn, A; Giladi, N; Inzelberg, R; Djaldetti, R; Klein, C; Berecz, G
      Rasagiline mesylate, a new MAO-B inhibitor for the treatment of Parkinson's disease: A double-blind study as adjunctive therapy to levodopa

      CLINICAL NEUROPHARMACOLOGY
    50. Tahar, AH; Gregoire, L; Bangassoro, E; Bedard, PJ
      Sustained cabergoline treatment reverses levodopa-induced dyskinesias in parkinsonian monkeys

      CLINICAL NEUROPHARMACOLOGY
    51. Hauser, RA; Friedlander, J; Zesiewicz, TA; Adler, CH; Seeberger, LC; O'Brien, CF; Molho, ES; Factor, SA
      A home diary to assess functional status in patients with Parkinson's disease with motor fluctuations and dyskinesia

      CLINICAL NEUROPHARMACOLOGY
    52. Reichmann, H; Lachenmayer, L
      The non-ergot-agonist ropinirole in the treatment of Parkinson's disease

      AKTUELLE NEUROLOGIE
    53. de la Fuente-Fernandez, R; Pal, PK; Vingerhoets, FJG; Kishore, A; Schulzer, M; Mak, EK; Ruth, TJ; Snow, BJ; Calne, DB; Stoessl, AJ
      Evidence for impaired presynaptic dopamine function in parkinsonian patients with motor fluctuations

      JOURNAL OF NEURAL TRANSMISSION
    54. Woitalla, D; Karwasz, R; Muller, T; Przuntek, H; Kuhn, W
      The activity of Catechol-O-Methyltransferase in parkinsonian patients with"on-off fluctuations"

      JOURNAL OF NEURAL TRANSMISSION
    55. Berchou, RC
      Maximizing the benefit of pharmacotherapy in Parkinson's disease

      PHARMACOTHERAPY
    56. Kashihara, K; Manabe, Y; Shiro, Y; Warita, H; Abe, K
      Effects of repeated methyl levodopa administration on apomorphine sensitivity of rotational behavior and striatal Fos expression of rats with unilateral 6-OHDA lesions

      NEUROSCIENCE RESEARCH
    57. Nutt, JG; Obeso, JA; Stocchi, F
      Continuous dopamine-receptor stimulation in advanced Parkinson's disease

      TRENDS IN NEUROSCIENCES
    58. Broussolle, E
      Dopa-therapy in the treatment of early stage Parkinson's disease

      REVUE NEUROLOGIQUE
    59. Brefel-Courbon, C
      What drug strategies are advisable for patients with advanced-stage Parkinsons's (working session)

      REVUE NEUROLOGIQUE
    60. Thobois, S
      Surgical treatments in Parkinson's disease

      REVUE NEUROLOGIQUE
    61. Blond, S; Touzet, G; Krystkowiak, P; Defebvre, L; Destee, A
      Neurosurgical treatment of Parkinson's disease: which technique is best?

      REVUE NEUROLOGIQUE
    62. Munchau, A; Bhatia, KP
      Pharmacological treatment of Parkinson's disease

      POSTGRADUATE MEDICAL JOURNAL
    63. Nieuwboer, A; De Weerdt, W; Dom, R; Bogaerts, K; Nuyens, G
      Development of an activity scale for individuals with advanced Parkinson disease: Reliability and "on-off" variability

      PHYSICAL THERAPY
    64. Kumar, R; Lang, AE; Rodriguez-Oroz, MC; Lozano, AM; Limousin, P; Pollak, P; Benabid, AL; Guridi, J; Ramos, E; van der Linden, C; Vandewalle, A; Caemaert, J; Lannoo, E; van den Abbeele, D; Vingerhoets, G; Wolters, M; Obeso, JA
      Deep brain simulation of the globus pallidus pars interna in advanced Parkinson's disease

      NEUROLOGY
    65. Rodriguez-Oroz, MC; Gorospe, A; Guridi, J; Ramos, E; Linazasoro, G; Rodriguez-Palmero, M; Obeso, JA
      Bilateral deep brain stimulation of the subthalamic nucleus in Parkinson'sdisease

      NEUROLOGY
    66. Koller, WC
      Levodopa in the treatment of Parkinson's disease

      NEUROLOGY
    67. Tsang, KL; Ho, SL; Lo, SK
      Estrogen improves motor disability in parkinsonian postmenopausal women with motor fluctuations

      NEUROLOGY
    68. Cersosimo, MG; Scorticati, MC; Micheli, FE
      Amantadine for the treatment of levodopa-induced dyskinesias in Parkinson's disease.

      MEDICINA-BUENOS AIRES
    69. Charlton, CG; Crowell, B
      Effects of dopamine metabolites on locomotor activities and on the bindingof dopamine: Relevance to the side effects of L-dopa

      LIFE SCIENCES
    70. Piccini, P; Brooks, DJ; Korpela, K; Pavese, N; Karlsson, M; Gordin, A
      The catechol-O-methyltransferase (COMT) inhibitor entacapone enhances the pharmacokinetic and clinical response to Sinemet CR in Parkinson's disease

      JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY
    71. Ravenscroft, P; Brotchie, J
      NMDA receptors in the basal ganglia

      JOURNAL OF ANATOMY
    72. Schrag, A; Quinn, N
      Dyskinesias and motor fluctuations in Parkinson's disease - A community-based study

      BRAIN
    73. Reardon, KA; Mendelsohn, FAO; Chai, SY; Horne, MK
      The angiotensin converting enzyme (ACE) inhibitor, perindopril, modifies the clinical features of Parkinson's disease

      AUSTRALIAN AND NEW ZEALAND JOURNAL OF MEDICINE
    74. Dodel, RC; Eggert, K; Oertel, WH
      Economical research on Parkinson's disease: a review of the literature

      EUROPEAN JOURNAL OF NEUROLOGY
    75. Wiseman, LR; Fitton, A
      Cabergoline - A review of its efficacy in the treatment of Parkinson's disease

      CNS DRUGS
    76. Durif, F
      Treating and preventing levodopa-induced dyskinesias - Current and future strategies

      DRUGS & AGING
    77. Liu, H; Iacono, RP; Schoonenberg, T; Kuniyoshi, S; Buchholz, J
      A comparative study on neurochemistry of cerebrospinal fluid in advanced Parkinson's disease

      NEUROBIOLOGY OF DISEASE
    78. Weiner, WJ
      The initial treatment of Parkinson's disease should begin with levodopa

      MOVEMENT DISORDERS
    79. Hagell, P; Widner, H
      Clinical rating of dyskinesias in Parkinson's disease: Use and reliabilityof a new rating scale

      MOVEMENT DISORDERS
    80. Agid, Y; Destee, A; Durif, F; Montastruc, JL; Pedarriosse, AM; Deptula, D; Hoffman-La Roche, F; Pollak, P; Bonnet, AM; Allain, H; le Cavorzin, P; Barroche, G; Blin, O; Cesaro, P; Chazot, G; Broussolle, E; Leduc, V; Debilly, B; Feve, JR; Geraud, G; Fabre, N; Gu, C; Gil, R; Henry, P; Tison, F; Ansquer, O; Brefel, C; Payen, I; Said, G; Plante, V; Touchon, J; Cesari, JB; Camu, W; Bennys, K; Viallet, F; Warter, JM; Tranchant, C; Ziegler, M
      Efficacy and tolerability of tolcapone compared with bromocriptine in levodopa-treated parkinsonian patients

      MOVEMENT DISORDERS
    81. Goetz, CG
      Rating scales for dyskinesias in Parkinson's disease

      MOVEMENT DISORDERS
    82. Widner, H; Defer, GL
      Dyskinesias assessment: From CAPIT to CAPSIT

      MOVEMENT DISORDERS
    83. Ceballos-Baumann, AO
      New aspects in the treatment of Parkinson's disease

      NERVENHEILKUNDE
    84. Contin, M; Riva, R; Martinelli, P; Cortelli, P; Albani, F; Baruzzi, A
      Concentration-effect relationship of levodopa-benserazide dispersible formulation versus standard form in the treatment of complicated motor responsefluctuations in Parkinson's disease

      CLINICAL NEUROPHARMACOLOGY
    85. Merello, M; Nouzeilles, MI; Cammarota, A; Leiguarda, R
      Effect of memantine (NMDA antagonist) on Parkinson's disease: A double-blind crossover randomized study

      CLINICAL NEUROPHARMACOLOGY
    86. Barboi, AC; Goetz, CG
      Clinical Neuropharmacology - Patient management series Parkinson's disease

      CLINICAL NEUROPHARMACOLOGY
    87. de la Fuente-Fernandez, R
      Drug-induced motor complications in dopa-responsive dystonia: Implicationsfor the pathogenesis of dyskinesias and motor fluctuations

      CLINICAL NEUROPHARMACOLOGY
    88. Ondo, W; Hunter, C; Almaguer, M; Gancher, S; Jankovic, J
      Efficacy and tolerability of a novel sublingual apomorphine preparation inpatients with fluctuating Parkinson's disease

      CLINICAL NEUROPHARMACOLOGY
    89. Napolitano, A; Del Dotto, P; Petrozzi, L; Dell'Agnello, G; Bellini, G; Gambaccini, G; Bonuccelli, U
      Pharmacokinetics and pharmacodynamics of L-DOPA after acute and 6-week tolcapone administration in patients with Parkinson's disease

      CLINICAL NEUROPHARMACOLOGY
    90. Manyam, BV; Hare, TA; Robbs, R; Cubberley, VB
      Evaluation of equivalent efficacy of Sinemet and Sinemet CR in patients with Parkinson's disease applying levodopa dosage conversion formula

      CLINICAL NEUROPHARMACOLOGY
    91. Mendis, T; Suchowersky, O; Lang, A; Gauthier, S
      Management of Parkinson's disease - A review of current and new therapies

      CANADIAN JOURNAL OF NEUROLOGICAL SCIENCES
    92. King, DB
      Parkinson's disease - Levodopa complications

      CANADIAN JOURNAL OF NEUROLOGICAL SCIENCES
    93. Neef, C; van Laar, T
      Pharmacokinetic-pharmacodynamic relationships of apomorphine in patients with Parkinson's disease

      CLINICAL PHARMACOKINETICS
    94. Fredriksson, A; Palomo, T; Chase, T; Archer, T
      Tolerance to a suprathreshold dose of L-Dopa in MPTP mice: effects of glutamate antagonists

      JOURNAL OF NEURAL TRANSMISSION
    95. Gottwald, MD
      Maximizing the benefit : risk ratio of levodopa therapy in Parkinson's disease

      PHARMACOTHERAPY
    96. Lee, WY; Chang, JW; Nemeth, NL; Kang, UJ
      Vesicular monoamine transporter-2 and aromatic L-amino acid decarboxylase enhance dopamine delivery after L-3,4-dihydroxyphenylalanine administrationin Parkinsonian rats

      JOURNAL OF NEUROSCIENCE
    97. Bonifati, V; Meco, G
      New, selective catechol-O-methyltransferase inhibitors as therapeutic agents in Parkinson's disease

      PHARMACOLOGY & THERAPEUTICS
    98. Broussolle, E
      Arguments favoring early treatment of Parkinson's disease with L-Dopa

      REVUE NEUROLOGIQUE
    99. Koller, WC; Hutton, JT; Tolosa, E; Capilldeo, R
      Immediate-release and controlled-release carbidopa/levodopa in PD - A 5-year randomized multicenter study

      NEUROLOGY
    100. Zappia, M; Oliveri, RL; Montesanti, R; Rizzo, M; Bosco, D; Plastino, M; Crescibene, L; Bastone, L; Aguglia, U; Gambardella, A; Quattrone, A
      Loss of long-duration response to levodopa over time in PD - Implications for wearing-off

      NEUROLOGY


ASDD Area Sistemi Dipartimentali e Documentali, Università di Bologna, Catalogo delle riviste ed altri periodici
Documento generato il 22/10/20 alle ore 20:44:10